Universal room-temperature stable influenza A nanovaccine
Is Version Of
Seasonal influenza A virus (IAV) is annually responsible for an estimated one billion infections, nine million hospitalizations, and 300,000 – 600,000 deaths annually. Considering the potential influenza pandemic threat, the development of a universal IAV vaccine is paramount to global public health. The work described herein forms the basis of a universal IAV subunit nanovaccine formulation composed of a novel equine IAV antigen and IAV nucleoprotein delivered via polyanhydride nanoparticles and pentablock copolymer micelles. This rationally designed subunit vaccine formulation was evaluated to determine both the release kinetics and the functional stability of antigenic loadings. The results described herein motivate the further investigation of this universal, room-temperature stable IAV nanovaccine.